New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs

Andrew V Schally, K. Szepeshazi, A. Nagy, A. M. Comaru-Schally, G. Halmos

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Cancers of the stomach, colon and exocrine pancreas are major international health problems and result in more than a million deaths worldwide each year. The therapies for these malignancies must be improved. The effects of gastrointestinal (GI) hormonal peptides and endogenous growth factors on these cancers were reviewed. Some GI peptides, including gastrin and gastrin-releasing peptide (GRP) (mammalian bombesin), appear to be involved in the growth of neoplasms of the GI tract. Certain growth factors such as insulin-like growth factor (IGF)-I, IGF-II and epidermal growth factor and their receptors that regulate cell proliferation are also implicated in the development and progression of GI cancers. Experimental investigations on gastric, colorectal and pancreatic cancers with analogs of somatostatin, antagonists of bombesin/GRP, antagonists of growth hormone-releasing hormone as well as cytotoxic peptides that can be targeted to peptide receptors on tumors were summarized. Clinical trials on peptide analogs in patients with gastric, colorectal and pancreatic cancers were reviewed and analyzed. It may be possible to develop new approaches to hormonal therapy of GI malignancies based on various peptide analogs.

Original languageEnglish
Pages (from-to)1042-1068
Number of pages27
JournalCellular and Molecular Life Sciences
Volume61
Issue number9
DOIs
StatePublished - May 1 2004
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Colonic Neoplasms
Stomach Neoplasms
Peptides
Gastrin-Releasing Peptide
Bombesin
Neoplasms
Colorectal Neoplasms
Intercellular Signaling Peptides and Proteins
Therapeutics
Exocrine Pancreas
Growth Hormone-Releasing Hormone
Insulin-Like Growth Factor II
Gastrointestinal Neoplasms
Peptide Receptors
Gastrins
Cell proliferation
Medical problems
Somatostatin
Insulin-Like Growth Factor I

Keywords

  • Bombesin/GRP antagonists
  • Gastrin
  • Gastrin-releasing peptide (GRP)
  • GH-RH antagonists
  • Somatostatin analogs
  • Targeted cytotoxic peptides

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Cell Biology

Cite this

New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs. / Schally, Andrew V; Szepeshazi, K.; Nagy, A.; Comaru-Schally, A. M.; Halmos, G.

In: Cellular and Molecular Life Sciences, Vol. 61, No. 9, 01.05.2004, p. 1042-1068.

Research output: Contribution to journalArticle

Schally, Andrew V ; Szepeshazi, K. ; Nagy, A. ; Comaru-Schally, A. M. ; Halmos, G. / New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs. In: Cellular and Molecular Life Sciences. 2004 ; Vol. 61, No. 9. pp. 1042-1068.
@article{0a7ac60c2ffd4c83889013496fa45576,
title = "New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs",
abstract = "Cancers of the stomach, colon and exocrine pancreas are major international health problems and result in more than a million deaths worldwide each year. The therapies for these malignancies must be improved. The effects of gastrointestinal (GI) hormonal peptides and endogenous growth factors on these cancers were reviewed. Some GI peptides, including gastrin and gastrin-releasing peptide (GRP) (mammalian bombesin), appear to be involved in the growth of neoplasms of the GI tract. Certain growth factors such as insulin-like growth factor (IGF)-I, IGF-II and epidermal growth factor and their receptors that regulate cell proliferation are also implicated in the development and progression of GI cancers. Experimental investigations on gastric, colorectal and pancreatic cancers with analogs of somatostatin, antagonists of bombesin/GRP, antagonists of growth hormone-releasing hormone as well as cytotoxic peptides that can be targeted to peptide receptors on tumors were summarized. Clinical trials on peptide analogs in patients with gastric, colorectal and pancreatic cancers were reviewed and analyzed. It may be possible to develop new approaches to hormonal therapy of GI malignancies based on various peptide analogs.",
keywords = "Bombesin/GRP antagonists, Gastrin, Gastrin-releasing peptide (GRP), GH-RH antagonists, Somatostatin analogs, Targeted cytotoxic peptides",
author = "Schally, {Andrew V} and K. Szepeshazi and A. Nagy and Comaru-Schally, {A. M.} and G. Halmos",
year = "2004",
month = "5",
day = "1",
doi = "10.1007/s00018-004-3434-3",
language = "English",
volume = "61",
pages = "1042--1068",
journal = "Cellular and Molecular Life Sciences",
issn = "1420-682X",
publisher = "Birkhauser Verlag Basel",
number = "9",

}

TY - JOUR

T1 - New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs

AU - Schally, Andrew V

AU - Szepeshazi, K.

AU - Nagy, A.

AU - Comaru-Schally, A. M.

AU - Halmos, G.

PY - 2004/5/1

Y1 - 2004/5/1

N2 - Cancers of the stomach, colon and exocrine pancreas are major international health problems and result in more than a million deaths worldwide each year. The therapies for these malignancies must be improved. The effects of gastrointestinal (GI) hormonal peptides and endogenous growth factors on these cancers were reviewed. Some GI peptides, including gastrin and gastrin-releasing peptide (GRP) (mammalian bombesin), appear to be involved in the growth of neoplasms of the GI tract. Certain growth factors such as insulin-like growth factor (IGF)-I, IGF-II and epidermal growth factor and their receptors that regulate cell proliferation are also implicated in the development and progression of GI cancers. Experimental investigations on gastric, colorectal and pancreatic cancers with analogs of somatostatin, antagonists of bombesin/GRP, antagonists of growth hormone-releasing hormone as well as cytotoxic peptides that can be targeted to peptide receptors on tumors were summarized. Clinical trials on peptide analogs in patients with gastric, colorectal and pancreatic cancers were reviewed and analyzed. It may be possible to develop new approaches to hormonal therapy of GI malignancies based on various peptide analogs.

AB - Cancers of the stomach, colon and exocrine pancreas are major international health problems and result in more than a million deaths worldwide each year. The therapies for these malignancies must be improved. The effects of gastrointestinal (GI) hormonal peptides and endogenous growth factors on these cancers were reviewed. Some GI peptides, including gastrin and gastrin-releasing peptide (GRP) (mammalian bombesin), appear to be involved in the growth of neoplasms of the GI tract. Certain growth factors such as insulin-like growth factor (IGF)-I, IGF-II and epidermal growth factor and their receptors that regulate cell proliferation are also implicated in the development and progression of GI cancers. Experimental investigations on gastric, colorectal and pancreatic cancers with analogs of somatostatin, antagonists of bombesin/GRP, antagonists of growth hormone-releasing hormone as well as cytotoxic peptides that can be targeted to peptide receptors on tumors were summarized. Clinical trials on peptide analogs in patients with gastric, colorectal and pancreatic cancers were reviewed and analyzed. It may be possible to develop new approaches to hormonal therapy of GI malignancies based on various peptide analogs.

KW - Bombesin/GRP antagonists

KW - Gastrin

KW - Gastrin-releasing peptide (GRP)

KW - GH-RH antagonists

KW - Somatostatin analogs

KW - Targeted cytotoxic peptides

UR - http://www.scopus.com/inward/record.url?scp=2442604328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442604328&partnerID=8YFLogxK

U2 - 10.1007/s00018-004-3434-3

DO - 10.1007/s00018-004-3434-3

M3 - Article

VL - 61

SP - 1042

EP - 1068

JO - Cellular and Molecular Life Sciences

JF - Cellular and Molecular Life Sciences

SN - 1420-682X

IS - 9

ER -